Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes.
Hunt says they're to increase the number of clinical sites in their PISCES III study from 25 to 40.
PISCES III is a phase IIb clinical study in the US of ReNeuron’s CTX cell therapy candidate for stroke disability.
First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.
Original Article: ReNeuron's Michael Hunt updates on product development
NEXT ARTICLE